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AbstrAct
Small interfering RNAs (siRNAs) are widely used to study gene function and 
extensively exploited for their potential therapeutic applications. HIPK2 is an 
evolutionary conserved kinase that binds and phosphorylates several proteins directly 
or indirectly related to apoptosis. Recently, an alternatively spliced isoform skipping 
81 nucleotides of exon 8 (Hipk2-∆e8) has been described. Selective depletion of 
Hipk2 full-length (Hipk2-FL) with a specific siRNA that spares the Hipk2-∆e8 isoform 
has been shown to strongly induce apoptosis, suggesting an unpredicted dominant-
negative effect of Hipk2-FL over the ∆e8 isoform. From this observation, we sought 
to take advantage and assessed the therapeutic potential of generating Hipk2 isoform 
unbalance in tumor-initiating cells derived from colorectal cancer patients. Strong 
reduction of cell viability was induced in vitro and in vivo by the originally described 
exon 8-specific siRNA, supporting a potential therapeutic application. However, 
validation analyses performed with additional exon8-specific siRNAs with different 
stabilities showed that all exon8-targeting siRNAs can induce comparable Hipk2 
isoform unbalance but only the originally reported e8-siRNA promotes cell death. 
These data show that loss of viability does not depend on the prevalence of Hipk2-
∆e8 isoform but it is rather due to microRNA-like off-target effects.
INtrODUctION
Colorectal cancer (CRC) is the third most 
common cancer globally with more than 1.2 million 
new cases diagnosed globally and roughly 600,000 
deaths occurring every year [1]. The prognosis of CRC 
patients has improved in the past decades with a 5-year 
relative survival greater than 90% in patients with 
stage I disease. These major advances have been achieved 
through multidisciplinary approaches, ranging from the 
improved screening to identify individuals at early stages 
to the development of targeted therapies [2]. Yet, there 
is still approximately a 10% 5-year relative survival rate 
in patients with stage IV disease [2] calling for further 
advances in prognostic and predictive markers and 
molecular targeted treatments. 
RNA interference (RNAi) is a sequence-specific, 
RNA-dependent gene-silencing process occurring in 
many eukaryotes, including humans [3]. In mammalian 
cells, RNAi can be mediated by short RNAs of about 
20 nucleotides that include endogenous microRNAs and 
exogenous short hairpin RNAs and synthetic siRNAs [4]. 
At the functional level, RNAi contributes to different 
physiological or pathological processes, including 
regulation of gene expression during differentiation 
and development, deregulation of oncogenes and tumor 
suppressor genes in tumorigenesis, cell defense against 
parasitic nucleotide sequences such as viruses and 
transposons [5, 6]. Given its selectivity in gene silencing, 
RNAi has become a potent and valuable research tool 
to study gene function both in cell culture and in living 
organisms [7]. Translation of this strategy into clinical 
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applications for disease treatment is being extensively 
exploited and a few siRNA-based specific gene silencing 
have entered clinical trials [8–11]. Indeed, significant 
improvement of delivery, bioavailability, and safety for the 
siRNA therapeutics has strongly stimulated the preclinical 
evaluation of a large body of siRNA targets with potential 
drug activity [12, 13]. This makes recognition of siRNA 
off-target effects a key aspect for both target identification 
and therapeutic applications [14].
Homeodomain-interacting protein kinase 2 (HIPK2) 
is a tyrosine-regulated serine/threonine kinase [15, 16] 
that phosphorylates a large body of proteins belonging to 
different networks, including transcriptional regulators, 
chromatin modifiers, signal transducers, and E3 components 
of SUMO ligases [17]. Data supporting a role for HIPK2 
as tumor suppressor have been obtained in mice where the 
hipk2 gene behaves as a haploinsufficient tumor suppressor 
in γ-irradiation-induced thymic lymphomagenesis [18], 
and in humans, where HIPK2 has been found inactivated 
by different mechanisms in different cancer types [19–21]. 
In response to genotoxic damage, HIPK2 stimulates p53–
depended and –independent cell cycle arrest and apoptosis 
[22–24] and specific reduction of HIPK2 expression by 
anti-sense oligonucleotides or RNAi was shown to impair 
apoptosis and induce resistance to different anticancer 
treatments [25, 26]. In a recent study regarding the role 
of the serine/arginine-rich splicing factor 3 in colon 
cancer cells [27], Kurokawa and colleagues uncovered the 
existence of an alternative splicing form of HIPK2, the 
Hipk2-∆e8 isoform, which is generated by the skipping of 
81 5′-nucleotides from exon 8. Interestingly, by employing 
a siRNA that hybridizes with the skipped exon 8 region 
and selectively depletes Hipk2-FL (here referred to as 
e8-siRNA#1), the authors observed a strong induction 
of apoptosis in both p53-proficient and -defective CRC 
cells [27]. Based on these data, the authors proposed 
that prevalence of Hipk2-∆e8 isoform expression over 
the FL one is a potent inducer of apoptosis [27]. Besides 
the mechanistic implications in the biological activity 
of HIPK2, this observation opens up to a stimulating 
opportunity to test the therapeutic efficacy of Hipk2-FL 
targeting siRNAs in human CRCs. 
Here, we investigated the therapeutic potential of 
the imbalance between Hipk2-∆e8 and Hipk2-FL isoforms 
induced by e8-siRNA#1 in a series of CRC cells including 
patient-derived tumor-initiating cells (i.e., Cancer Stem 
Cells – CSCs) [28]. We confirm the loss of viability 
in vitro by e8-siRNA#1 (Hipk2 siRNA#2 in Kurokawa 
et al.) and further show its ability to efficiently reduce 
the growth of CSC-derived tumor xenografts in vivo. 
However, target validation experiments performed by 
employing multiple individual siRNAs targeting the same 
skipped exon 8 region of Hipk2 showed a comparable 
unbalance between Hipk2-∆e8 and Hipk2-FL isoforms but 
no sign of cell death, demonstrating that loss of viability is 
due to off-target effects.
rEsULts
To explore the potential therapeutic activity of Hipk2-
FL specific targeting by siRNA in CRCs, we first evaluated 
the expression of the two Hipk2 isoforms, Hipk2-FL and 
Hipk2-∆e8, in three patient-derived colorectal CSCs (CSC1, 
CSC2, and CSC3) [29]. In this and in further experiments, 
we included the HCT-116 cells for a direct comparison with 
the already reported results [27] and the p53-null H1299 
cells and the wild-type p53-carrying U2OS cells to verify 
the generality and the p53-independency of the cell death 
induced by Hipk2 isoform-unbalance. Due to the absence 
of HIPK2 isoform-specific antibodies [27], RT-PCR was 
performed with primers external to the spliced region of 
exon 8 to check for Hipk2 isoform expression. Both Hipk2 
isoforms were detected in all the analyzed cells (Figure 1A). 
In addition, Real Time quantitative PCR analysis showed that 
the relative ratio between the FL and ∆e8 Hipk2 isoforms 
varies between 0.7 and 2.1 in tested cells (Figure 1B). This 
result provides the possibility of triggering an e8-siRNA#1-
induced imbalance of the Hipk2 isoforms and verify its 
therapeutic efficacy at the preclinical level. 
e8-sirNA#1 induces cells death in crc cells 
Selective depletion of Hipk2-FL by e8-siRNA#1 
was shown to induce apoptosis in p53-proficient and p53–
defective cells [27]. To assess whether this effect can be 
extended to patient-derived CSCs and eventually employed 
as targeted drugs in CRCs, CSCs were transfected 
with each of the following Hipk2-specific siRNAs that 
hybridize with three different regions: a siRNA targeting 
both isoforms on exon 7 (e7-siRNA), a siRNA targeting 
the skipped exon 8 present only in the Hipk2-FL isoform 
(e8-siRNA#1), and a siRNA targeting the junction 
between exon 7 and exon 8 (e7/8-siRNA) present only 
in the Hipk2-∆e8 isoform (Figure 2A). A siRNA with a 
scrambled sequence of e8-siRNA#1 was used as control. 
At 72 hrs post-transfection, cells were collected and 
analyzed by RT-PCR for Hipk2 isoform expression and by 
Western blotting (WB) for apoptotic markers (i.e., cleaved 
forms of Caspase 3 and β-Catenin) [30]. Representative 
results obtained with CSC1 cells are reported in Figure 2B 
and show that the three Hipk2-specific siRNAs efficiently 
deplete Hipk2 isoforms as predicted from their respective 
annealing sequences (Figure 2A–2B). Consistently with 
the data reported by Kurokawa and colleagues [27], only 
the e8-siRNA#1 that selectively depletes the Hipk2-FL 
isoform was associated with strong loss of viability and 
the appearance of apoptotic markers (Figure 2B). Loss 
of viability induced by e8-siRNA#1 transfection and the 
induction of apoptotic markers (i.e., cleaved forms of 
Caspase 3 and PARP1) were confirmed in all the cells 
employed and the amount of cell death was proportional 
to the transfection efficiency (Figure 2C–2D), making 
unlikely a cell-specific response. 
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Considering that the patient-derived CSCs are 
usually maintained as spheres in strictly defined, serum-
free medium [28], we compared the amount of cell death 
induced by the e8-siRNA#1-treatment in CSCs cultured 
as spheres in low-adherence plates without serum, or 
maintained in adherent conditions and in the presence 
of fetal bovine serum (FBS). No significant differences 
were observed in the loss of viability in the two culturing 
conditions (Figure 2E), indicating that in these CRC cells 
the e8-siRNA#1-induced death is both substrate and 
growth factor independent.
e8-sirNA#1 reduces tumor growth in csc-
derived tumor xenograft 
To begin evaluating the possible therapeutic 
efficacy of e8-siRNA#1-treatment in vivo, patient-
derived CSC1 cells were stably transfected with a 
luciferase reporter vector to allow in vivo imaging [31] 
and then injected subcutaneously into nude mice. 
Seven days post-injection, when tumors were palpable 
and visible by bioluminescence imaging, mice were 
intratumorally injected with the e8-siRNA#1 using 
RNAi-Max Lipofectamine as a delivery vehicle. A 
scrambled sequence of e8-siRNA#1 (Scr-siRNA) was 
used as control. Compared to control, e8-siRNA#1 
treatment strongly reduced tumor growth measured 
by both tumor calibration (Figure 3A) and luciferase 
intensity (Figure 3B). This effect was confirmed by direct 
explanted tumors comparison fifteen days after the first 
treatment, showing a reduction in size and decreased 
vascularization in the e8-siRNA#1-treated CSC1 tumor 
xenografts (Figure 3C). These results emphasize that at 
least the direct intratumor injection of the e8-siRNA#1 can 
be therapeutically effective in a tumor xenograft model, 
calling for further preclinical tests.
target validation reveals a clear off-target cell 
death activity of the e8-sirNA#1
The use of multiple individual siRNAs targeting the 
same gene is considered a straightforward approach for 
target validation [32]. Thus, before proceeding to more 
demanding preclinical experiments, we performed further 
Figure 1: both Hipk2 rNA isoforms are expressed in tumor cell lines and patient-derived colon cscs. (A) Expression of 
Hipk-2-FL and Hipk2-∆e8 isoform were measured by RT-PCR using a primer set which amplifies the alternatively spliced region of exon 8. 
Gapdh was used as loading control. (b) Quantitative  Real Time-PCR analysis with isoform-specific primers was used to determine the 
relative ratio of  Hipk2-FL and Hipk2-∆e8 mRNA expression.
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Figure 2: the e8-sirNA#1 targeting the Hipk2-FL isoform induces cell death in tumor cells and colon cscs. 
(A) Schematic representation of Hipk2 isoforms in the alternative spliced region. Bars indicate the relative annealing position of siRNAs 
targeting both isoforms (e7-siRNA), the FL isoform (e8-siRNA#1) or the ∆8 isoform (e7/8-siRNA), respectively. (b) CSC1 were transfected 
with the indicated siRNAs and collected after 72 hrs. Cells from the same plate were counted to assess viability and analyzed by both RT-
PCR, to check for specific Hipk2 isoform depletion and WB, to detect apoptosis. Cleaved CASPASE 3 (clvd CASP3) and β-CATENIN 
(clvd β-CAT) were used as apoptotic markers, while Gapdh and β-ACTIN were used as loading controls. (c) Cell were transfected with 
e8-siRNA#1 or its scrambled version (Scr-siRNA) and collected after 72 hrs. Cell viability was determined by Trypan-blue exclusion test. 
Values are expressed as means ± standard deviation (S.D.) (n = 3). (D) Cell were transfected as in C and analyzed by RT-PCR, to check 
for specific Hipk2 isoform depletion and by WB, to detect apoptosis. Cleaved CASPASE 3 (clvd CASP3) and PARP-1 (clvd PARP1) were 
used as apoptotic markers, Gapdh and β-ACTIN were used as loading controls. A fluorescent oligo was co-transfected with the control 
siRNA to check for transfection efficiency. (E) CSC1 cells were cultured as spheroids in the absence of serum in low-adherence plates 
(upper panels) or let attach on standard tissue culture plates in the presence of serum (bottom panels) and compared for their sensibility to 
e8-siRNA apoptotic effect. Pictures were taken after three days of treatment. The percentage of viability is indicated at the bottom of each 
panel.  Bars, 100 μm
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target validation tests to increase our confidence in the 
validity and specificity of the cell death induced by e8-
siRNA#1-treatment. To this aim, three more Hipk2-FL-
specific siRNAs (i.e., e8-siRNA#2, #3 and #4) that also 
hybridize within the skipped exon 8 region (Figure 4A) 
were produced and tested on CSC1 and CSC2 cells for 
stimulation of both Hipk2 isoform imbalance and loss of 
viability. In agreement with the data reported [27], each 
of the four employed siRNAs comparably repressed the 
Hipk2-FL expression, sparing the Hipk2-∆e8 isoform 
(Figure 4B, upper panels). Disappointingly, only the 
original e8-siRNA#1 was able to induce cell death, as 
shown by evaluation of Caspase 3, PARP1 and β-Catenin 
cleavage (Figure 4B, lower panels) and cell viability 
(Figure 4C), clearly indicating an off-target apoptotic 
activity of this specific siRNA. Thus, we first verified a 
possible lack of specificity due to mRNA degradation 
mediated by partial sequence complementation. An 
in silico search for annealing sequences of the e8-siRNA#1 
with nonspecific genes showed a 64% complementation 
with the NR1D2 (nuclear receptor subfamily 1, group D, 
member 2) gene (Figure 5A). NR1D2 is a DNA-binding 
transcriptional regulator involved in metabolic functions, 
inflammatory response, and circadian rhythm [33]. 
However, when we assessed the NR1D2 mRNA levels 
after e8-siRNA#1 transfection, no reduction of expression 
was observed (Figure 5B). 
Next, we evaluated the possibility that the high 
stability of the chemically modified e8-siRNAs used by 
Kurokawa and by our group (see Materials and Methods) 
might be responsible for the off-target-induced cell 
death. CSC1 and CSC2 cells were transfected with the 
chemically modified Stealth RNAi (e8-siRNA#1) or with 
the corresponding, unmodified siRNA (#1U). As shown in 
Figure 4B (lanes 2, 3 and 8, 9) and Figure 4C, comparable 
results were obtained with the two siRNA preparations in 
both cell populations ruling out a major effect due to high 
siRNA stability. 
Eventually, we tested whether the pro-apoptotic 
activity of HIPK2 is required for the e8-siRNA#1-
induced cell death. To this aim, we employed the parental 
Hap- 1 cells (Hipk2-WT) and their Hipk2-KO derivatives, 
obtained by Hipk2 exon 3 deletion through the CRISPR-
Cas9 technology (see Materials and Methods). As shown 
in Figure 5C, e8-siRNA#1 similarly reduced cell viability 
in both cell types, indicating that the presence of neither 
of Hipk2 isoform is necessary for e8-siRNA#1-induced 
cell death. As further control, we generated an unbalance 
between the Hipk2 isoforms by their overexpression 
rather than silencing. As shown in Figure 5D, the GFP-
tagged version of both HIPK2-FL and HIPK2-∆e8 
isoforms significantly reduced BrdU incorporation when 
expressed in U2OS cells, supporting a similarity of action 
between the two isoforms.
Figure 3: treatment with e8-sirNA#1 inhibits tumor growth in vivo. Patient derived CSC1 cells stably transfected with a 
luciferase reporter vector were inoculated into athymic mice. Twice a week mice were intratumorally treated with e8-siRNA (n = 6). A 
scrambled version of e8-siRNA (Scr-siRNA) was used as control (n = 6). (A) Tumor volume in nude mice treated with e8-siRNA or with 
Scr-siRNA. Xenograft growth was monitored and showed as mean ± S.D. *p < 0.01. (b) Bioluminescence imaging of three representative 
mice for each group at 0 and 13 days of treatment. Luciferase imaging of mice whole body was performed twice a week. (c) Comparison 
of tumors explanted from Scr-siRNA and e8-siRNA#1 treated mice fifteen days after the first treatment. Three representative tumors for 
each group are shown. 
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Taken together, these results show that loss of 
viability induced by the e8-siRNA#1 does not depend on the 
unbalance between Hipk2 isoforms but it is rather caused by 
off-target activity of this specific siRNA sequence. 
the e8-sirNA#1 off-target activity has no 
therapeutic window 
Recognizing and avoiding siRNA off-target effects 
is mandatory to elucidate gene function. Interestingly, this 
absoluteness was shown to be less relevant for therapeutic 
applications [34]. In a last attempt to translate the strong 
reduction of cell viability induced by e8-siRNA#1 in 
cancer cells in vitro and in vivo into a therapeutic strategy 
for CRCs, we asked whether this treatment possesses a 
therapeutic window (i.e., normal cells are significantly less 
susceptible than cancer cells to the e8-siRNA#1-induced 
cell death). Off-target transcript regulation by siRNAs 
was shown to be species-specific and preclinical mouse 
models might not predict human off-target activity [35]. 
Thus, we analyzed the effect induced by e8-siRNA#1 
and the other e8-specific siRNAs on the viability of non-
tumor, primary human umbilical vein endothelial cells 
(HUVECs), and immortalized human dermal fibroblasts 
Figure 4: The use of different siRNAs targeting the same exon 8 region reveals that Hipk2-FL depletion is not sufficient 
to prompt apoptosis. (A) Four different siRNAs homologous to a short region of Hipk2 exon 8 present only in the FL isoform were used 
for target validation. The sequence of each e8-siRNA is highlighted in red. (b) Two CSC lines were transfected with the indicated siRNAs. 
All siRNAs were used as Stealth RNAi from Invitrogen, with the exception of e8-siRNA#1U, which is a standard unmodified version of 
e8-siRNA#1. Cells were collected after 72 hrs, counted to assess viability and analyzed by both RT-PCR and WB. Cleaved CASPASE 3 
(clvd CASP3) and β-CATENIN (clvd β-CAT) and PARP1 (Clvd PARP) were used as apoptotic markers. (c) Light microscopy pictures of 
transfected cells taken 96 hrs post-transfection reveal a clearly different phenotypic aspect in cells treated with different siRNA targeting 
the same RNA region. The percentage of viable cells is reported at the right bottom of each panel. Bars, 100 μm.
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(HFs). As observed with cancer cells, both HUVECs 
and HFs showed clear and comparable repression of 
the Hipk2-FL isoform with all the employed e8-specific 
siRNAs and significant loss of viability only with the 
e8-siRNA#1 (Figure 6). These results show that the 
off-target-dependent cell death induced by e8-siRNA#1 is 
comparable between cancer and “normal” cells showing 
on one side, a broad consistency of this result, and, on 
the other side, the absence of a therapeutic window that 
strongly discourages further preclinical testing.
Figure 5: Evaluation of the e8-sirNA#1 off-target effect. (A) Sequence alignment between Hipk2 e8siRNA#1 and Nr1D2 in 
the homologous region. (b) CSC1 cells were transfected with the indicated siRNAs. At 96 hrs post-transfection, Hipk2-FL and Nr1D2 
expression were monitored by RT-PCR. (c) Hap-1 parental (Hipk2-WT) and Hipk2-KO cells were transfected with e8-siRNA#1 or its 
scrambled version (Scr-siRNA) and collected after 72 hrs. Cells were counted to assess viability and analyzed by both RT-PCR and WB. 
Cleaved CASPASE 3 (clvd CASP3) was used as apoptotic marker. Deletion of exon 3 in Hipk2-KO cells was confirmed by specific primers 
(Hipk2 e3). (D) U2OS cells were transfected with GFP-tagged constructs for HIPK2-FL (GFP-FL) and HIPK2-∆e8 (GFP-∆8) isoforms. 
HIPK2 expressing cells were identified by GFP expression. BrdU positive, proliferating cells, were detected by immunofluorescence with 
an anti-BrdU antibody. Representative fluorescent images are reported in the right panels. Bars, 10 μm.
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DIscUssION
In this study, we investigated whether the prevalence 
of HIPK2-Δe8 isoform induced by HIPK2 FL-specific 
siRNA can have therapeutic effects in CRC cells. 
HIPK2 is an effective player in cell response 
to genotoxic agents that can sense damage intensity 
and involved in the choice between cell cycle arrest 
and apoptosis in p53-dependent and –independent 
manners [36]. Besides posttranslational modifications 
and subcellular localization, HIPK2 activity is tightly 
controlled by the ubiquitin–proteasome system and 
multiple HIPK2-targeting E3 ligases have been 
characterized [37]. Recently, two alternative splicing 
forms of HIPK2 with different sensitivity to the E3 
ubiquitin ligase Siah-1 have been described, the Hipk2-FL 
and the Hipk2-∆e8 isoform, that lacks the 27 aminoacids 
required for Siah-1-binding, thus becoming resistant to 
proteasome digestion [27]. It is important to note that, 
by employing a specific siRNA that selectively depletes 
Hipk2-FL, a strong induction of apoptosis was observed in 
CRC cell lines highlighting a potential therapeutic strategy 
for CRCs, even against mutant p53-carrying tumors 
[27]. We took up the challenge of testing this hypothesis 
on patient-derived colorectal cancer stem cells, whose 
profiles have been shown to be highly prognostic for CRC 
patients [38]. We were able to confirm the existence of 
the two alternative splicing forms of Hipk2 in these CSCs 
as well as in cells from tumor lines or primary normal 
HUVEC and immortalized HFs (Figures 1 and 6). In 
addition, transfection with the originally employed Hipk2-
FL-specific e8-siRNA#1 induces the reported imbalance 
between Hipk2-FL and the Hipk2-∆e8 isoforms that is 
associated with loss of viability both in vitro and in vivo 
(Figures 2, 3, and 6). Thus, we could easily reproduce the 
results obtained by Kurokawa and coworkers [27] in all 
the cells in which we performed these experiments. 
The on-target specificity of the Hipk2-FL-specific e8-
siRNA was originally assessed at the gene-expression level 
by employing two individual siRNAs targeting the skipped 
exon 8 region of Hipk2 and demonstrating a comparable 
imbalance between Hipk2 isoforms [27]. However, at the 
phenotypic level, i.e. the apoptotic outcome, only a single 
siRNA, the HIPK2 siRNA#2 (here named e8-siRNA#1) 
was employed [27], making the exclusion of possible off-
target effects unreliable. Indeed, when we attempted to 
validate the target-specificity of e8-siRNA#1 by employing 
three additional e8-specific siRNAs, we also found that 
Figure 6: Non-tumor cell are sensitive to the apoptotic effect of e8-sirNA#1. Human immortalized fibroblast (HF) and primary 
endothelial cells (HUVEC) were transfected with the indicated siRNAs. (A) At 96 hours post-transfection viability was assessed and 
the Hipk2-FL depletion monitored by RT-PCR. (b) Light microscopy pictures of transfected cells taken 96 hrs post-transfection. The 
percentage of viable cells is reported at the right bottom of each panel. Bars, 100 μm.
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each siRNA was able to knockdown the expression of 
Hipk2-FL sparing the Hipk2-∆e8 isoforms. However, 
only the originally described e8-siRNA#1 reduces cell 
viability indicating that its apoptotic activity is caused by 
off-target effects (Figure 4). In addition, as demonstrated 
by experiments performed in Hipk2-KO cells, the e8-
siRNA#1 strongly reduces cell viability even in the 
absence of HIPK2. This further reinforces the concept that 
the apoptotic effect is not caused by an unbalance between 
the two isoforms but is, indeed, HIPK2-independent. 
Thought less intriguing, this conclusion is coherent with 
the observation originally made by Kurokawa [27] and 
confirmed by us, here, showing that the two isoforms have 
similar activity upon their overexpression. 
A growing body of evidence demonstrates that siRNA 
specificity is not absolute and off-target gene silencing 
can occur through different mechanisms, such as mRNA 
degradation mediated by partial sequence complementation, 
immune stimulation by interferon response, microRNA-
like inhibition of translation, and saturation of the RNAi 
machinery [14]. In an attempt to characterize the off-target 
activity of the e8-siRNA#1, we observed that its lack of 
specificity is not due to partial sequence complementation 
and subsequent off-target mRNA degradation (Figure 5). 
Since loss of viability induced by e8-siRNA#1 was present 
both in vitro and in vivo in cells of non-immune origin 
(Figures 2, 3, and 6), we can exclude an immune stimulation-
based off-target activity. The e8-siRNA#1 employed in the 
original work by Kurokawa [27] and by our group in our 
in vitro and in vivo experiments are chemically modified 
Stealth RNAi™ produced by Invitrogen. This type of 
modification, which is a company property, provides 
increased stability. Thus, we directly tested and 
experimentally ruled out the possibility that such stability 
might be responsible for off-target-induced cell death by 
saturation of the RNAi machinery, a further mechanism 
of off-target gene silencing [39]. By exclusion, at least to 
our current knowledge of the phenomenon, the remaining 
mechanism that may explain the e8-siRNA#1 off-target 
effect is the microRNA-like activity. siRNAs have been 
shown to repress subsets of genes by acting like microRNAs 
and inducing, in addition to the cleavage of the intended 
target, the translational repression of several unintended 
targets [40]. While the first effect is the result of a perfect 
base-pairing, the second is due to the sequence-dependent 
interaction of siRNA with non-intended targets through a 
few nucleotide sequence of the 5′ end of the siRNA guide 
strand. Our approach towards target validation also supports 
the hypothesis that the e8-siRNA#1 induces apoptosis by 
microRNA-like off-target activity. Indeed, the three further 
individual siRNAs we employed to target the same Hipk2-
FL gene partially overlaps the original e8-siRNA sequence. 
The small slide on the gene sequence of the additional 
siRNAs (Figure 4A) allowed the maintenance of the Hipk2-
FL specific repression but was sufficient to avoid cell-death, 
showing that a few nucleotide differences are sufficient to 
overcome the off-target activity. 
Further analyses, such as RNA deep-sequencing, 
would have proven the hypothesis that e8-siRNA#1 
induces cell death by microRNA-like activity. This type of 
characterization would have been essential in the case of a 
therapeutic application for CRC treatment. Indeed, it has 
been proposed that the need in recognizing and avoiding 
siRNA off-target effects is mandatory in the process of 
elucidating gene function but might be less relevant for 
therapeutic applications and some “undesirable” off-target 
effects might even become useful in medical strategy [34]. 
We took this option into consideration and began assessing 
the therapeutic window of the e8-siRNA#1-treatment by 
comparable siRNA transfection of cancer and “normal” 
human cells. Disappointingly for the translational 
approach, we have found comparable evidence of loss 
of viability in both cell types strongly persuading against 
further analyses. Conversely, these observations highlight 
the broad consistency of the e8-siRNA#1 off-target 
activity, claiming, once more, for the need for validating 
depletion experiments with multiple tools and assessing 
the consistency of both molecular and functional readouts.
MAtErIALs AND MEtHODs
cell culture and transfection
HCT116, H1299, U2OS cell lines and HF 
(immortalized Human Fibroblasts) were cultured in 
DMEM supplemented with 10% (v/v) FBS and antibiotics. 
HUVEC (Human Umbilical Cord Derived Endothelial 
cells) were cultured in EBM2 medium (Lonza). Hipk2- KO 
cells containing a frame shift mutation in Hipk2 exon 3 
and their parental Hap1 cells were purchased from 
Horizon Genomics and cultured in IMDM medium 
supplemented with 10% FBS. To obtain CSCs, tumor 
samples were subjected to mechanical and enzymatic 
dissociation. The resulting cancer cells were cultured in a 
serum-free medium supplemented with 20 ng/ml EGF and 
10 ng/ml FGF-2 (PrePro-Tech) [28]. Chemically modified 
Stealth RNAi (Invitrogen) or unmodified siRNAs (MWG 
Operon, Eurofin) were used for cell transfection with 
RNAi-MAX Lipofectamine (Invitrogen), according to 
manufacturer’s instructions. BLOCK-iT Red Fluorescent 
oligo (Invitrogen) was used to measure RNA transfection 
efficiency. N-terminal GFP-tagged HIPK2-FL and 
HIPK2-∆e8 expression vectors were obtained by cloning 
human Hipk2 cDNAs into pEGFP-c2 (Clontech) and 
confirmed by direct sequencing. Cells were transfected by 
Lipofectamine LTX and Plus reagent (Invitrogen).
rt–Pcr 
Total RNA was isolated using the RNeasy mini Kit 
(Qiagen). cDNA was synthesized from using a M-MLTV 
RTase and amplified with GoTaq DNA polymerase 
(Promega) Primer sequences are as follows: 
Hipk2-FW GGCTGACCGGCGGGAGTT, 
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Hipk2-REV GGTCAGGCCGGGCACAAATCT 
(NCBI Ref Seq NM_022740.4);
NR1D2-FW AGTGAGAAGCTAAATGCCCTCC, 
Nr1D2 REV TATCAGGGAGATGCAGTCAACG 
(NCBI Ref Seq NM_001145425.1).
For quantitative PCR analysis, mRNA expression 
level was evaluated using Power SYBR Green PCR 
master mix with ABI Prism 7500HT Fast Real-Time PCR 
System Detector (Applied Biosystems). Gene expression 
was quantified using the 2-∆∆Ct methods. Gapdh was 
used as endogenous reference gene. Primers sequences 
(Ref Seq: NM_001113239, NM_022740) are as follows: 
Hipk2-FL-FW: TGACCATGACCTTTAACAACCA
Hipk2-FL-REV: GCTAAGGAAATAGTGGCACTGG
Hipk2-∆8-FW: TGACCACTGTCCACAACCAG 
CCCTCAG
Hipk2-∆8-REV: TCGCACCGAGTAGCCAGCGTGC
Western blotting
Whole-cell lysates were prepared using RIPA buffer 
containing a protease and phosphatase inhibitor mixture 
(Roche Applied Science). The extracted proteins were 
separated by SDS-PAGE and then transferred onto a 
nitrocellulose membrane (Bio-Rad). After blocking for 
1 hr at room temperature with 5% non-fat milk (Bio-
Rad), membranes were incubated overnight at 4°C with 
the indicated antibodies. Following incubation with 
an appropriate secondary antibody for 1 hr at room 
temperature, bound antibodies were detected with an 
ECL WB Detection System (GE Healthcare). Apoptosis 
was evaluated by measuring cleaved Caspase-3 (Cell 
Signaling Technology), PARP-1 and β-Catenin (Abcam) 
levels. β-actin (Santa Cruz Biotecnology) was used as a 
loading control. 
Animal maintenance and tumor xenografts
Six-week old nu/nu male mice were purchased from 
Charles River and housed with laboratory chow and water 
available ad libitum. All procedures involving mice were 
performed in compliance with our institutional animal 
care guidelines and following national and international 
directives (D.L. March 4, 2014, no. 26; directive 2010/63/
EU of the European parliament and of the council; Guide 
for the Care and Use of Laboratory Animals, United States 
National Research Council, 2011). Tumor xenografts 
were established by injecting subcutaneously into the 
right flank of mice 1 × 106 patient-derived CSC1 cells 
stably transfected with a luciferase reporter vector [31] 
mixed with Matrigel (BD Biosciences). Seven days post 
injection, when tumors reached about 40 mm3 and were 
detectable by bioluminescent imaging, animals were 
randomized into two groups (n = 6 in each group), one 
receiving e8siRNA#1 and the other receiving a control 
siRNA (Scrambled-siRNA). siRNAs (10 μg/mouse) were 
intratumorally injected as complexes with 5 μl of RNAi-
Max Lipofectamine. The injection protocol was performed 
twice a week for two weeks. 
Tumor dimensions were measured using a digital 
caliper and tumor volume was calculated before each 
intratumoral injection. Tumor growth was also monitored 
by bioluminescent imaging as previously described [31]. 
Data were expressed as photon/second/cm2/steradiant 
(p/s/cm2/sr) and the scale used in each experiment is 
reported in the corresponding figures. Luciferase imaging 
was performed twice a week. Fifteen days after the first 
treatment mice were sacrificed and tumors were explanted, 
photographed and weighed.  
statistical analyses
For comparison between two independent groups, 
the Student’s t-test was used.
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